LigaChem Biosciences (formerly LegoChem Biosciences) is a clinical-stage biopharmaceutical company specializing in innovative medicinal chemistry. We are focused on developing novel antibody-drug conjugate (ADC) technologies that address significant challenges faced by current ADC platforms. Our diverse pipeline encompasses next-generation ADC products, antibiotics, and anti-fibrotic therapies, all driven by our proprietary technology designed to enhance efficacy and safety in oncology and other therapeutic areas.